Arcellx Inc. is a clinical-stage biotechnology company. The Company is focused developing controllable cell therapies for the treatment of patients with cancer and other incurable diseases.
Company profile
Ticker
ACLX
Exchange
Website
CEO
Rami Elghandour
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Subdomain, LLC ...
IRS number
472855917
ACLX stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
11 Apr 24
DEFA14A
Additional proxy soliciting materials
11 Apr 24
DEF 14A
Definitive proxy
11 Apr 24
8-K
Changes in Registrant's Certifying Accountant
14 Mar 24
10-K
2023 FY
Annual report
28 Feb 24
8-K
Arcellx Provides Fourth Quarter and Year-End 2023 Financial Results and Business Highlights
28 Feb 24
8-K
Termination of a Material Definitive Agreement
31 Jan 24
S-8
Registration of securities for employees
2 Jan 24
8-K
Other Events
28 Dec 23
8-K
Other Events
12 Dec 23
Latest ownership filings
4
Olivia C Ware
18 Apr 24
SC 13G/A
FMR LLC
10 Apr 24
4
Rami Elghandour
3 Apr 24
144
Notice of proposed sale of securities
1 Apr 24
4
Christopher Heery
26 Mar 24
SC 13D/A
SR ONE CAPITAL MANAGEMENT, LLC
25 Mar 24
4
Jill Carroll
25 Mar 24
144
Notice of proposed sale of securities
22 Mar 24
144
Notice of proposed sale of securities
21 Mar 24
144
Notice of proposed sale of securities
21 Mar 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 131.05 mm | 131.05 mm | 131.05 mm | 131.05 mm | 131.05 mm | 131.05 mm |
Cash burn (monthly) | 58.37 mm | (no burn) | 14.95 mm | 12.07 mm | 3.37 mm | (no burn) |
Cash used (since last report) | 399.58 mm | n/a | 102.37 mm | 82.65 mm | 23.05 mm | n/a |
Cash remaining | -268.54 mm | n/a | 28.68 mm | 48.40 mm | 108.00 mm | n/a |
Runway (months of cash) | -4.6 | n/a | 1.9 | 4.0 | 32.1 | n/a |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 138 |
Opened positions | 17 |
Closed positions | 21 |
Increased positions | 59 |
Reduced positions | 38 |
13F shares | Current |
---|---|
Total value | 1.66 tn |
Total shares | 58.73 mm |
Total puts | 5.30 k |
Total calls | 22.80 k |
Total put/call ratio | 0.2 |
Largest owners | Shares | Value |
---|---|---|
FMR | 4.54 mm | $162.80 bn |
Perceptive Advisors | 3.97 mm | $142.30 bn |
SR One Capital Management | 3.95 mm | $174.24 mm |
SR One Capital Management | 3.95 mm | $141.61 bn |
NEA Management | 3.75 mm | $134.38 bn |
New Enterprise Associates 15 | 3.75 mm | $165.99 mm |
GILD Gilead Sciences | 3.48 mm | $115.27 mm |
Paradigm Biocapital Advisors | 2.95 mm | $105.96 bn |
Suvretta Capital Management | 2.87 mm | $102.97 bn |
BLK Blackrock | 2.71 mm | $97.15 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
16 Apr 24 | Olivia C Ware | Common Stock | Sell | Dispose S | No | Yes | 56.031 | 2,612 | 146.35 k | 0 |
16 Apr 24 | Olivia C Ware | Common Stock | Sell | Dispose S | No | Yes | 55.3618 | 6,790 | 375.91 k | 2,612 |
16 Apr 24 | Olivia C Ware | Common Stock | Option exercise | Acquire M | No | No | 7.61 | 9,402 | 71.55 k | 9,402 |
16 Apr 24 | Olivia C Ware | Stock Option Common Stock | Option exercise | Dispose M | No | No | 7.61 | 9,402 | 71.55 k | 36,806 |
1 Apr 24 | Rami Elghandour | Common Stock | Sell | Dispose S | No | Yes | 68.4161 | 2,711 | 185.48 k | 69,253 |
1 Apr 24 | Rami Elghandour | Common Stock | Sell | Dispose S | No | Yes | 67.5827 | 5,456 | 368.73 k | 71,964 |
1 Apr 24 | Rami Elghandour | Common Stock | Sell | Dispose S | No | Yes | 66.672 | 14,919 | 994.68 k | 77,420 |
26 Mar 24 | Heery Christopher | Common Stock | Sell | Dispose S | No | Yes | 70.1866 | 861 | 60.43 k | 8,938 |
26 Mar 24 | Heery Christopher | Common Stock | Sell | Dispose S | No | Yes | 69.3604 | 2,034 | 141.08 k | 9,799 |
26 Mar 24 | Heery Christopher | Common Stock | Sell | Dispose S | No | Yes | 68.5473 | 2,555 | 175.14 k | 11,833 |
News
Peering Into Arcellx's Recent Short Interest
15 Apr 24
Needham Reiterates Buy on Arcellx, Maintains $81 Price Target
11 Apr 24
Needham Maintains Buy on Arcellx, Raises Price Target to $81
18 Mar 24
Stifel Reiterates Buy on Arcellx, Maintains $82 Price Target
14 Mar 24
Arcellx's Lead Asset Can Potentially Outperform Bristol-Myers Squibb, Johnson & Johnson's Multiple Myeloma Cell Therapies: Morgan Stanley
7 Mar 24
Press releases
Arcellx to Participate in the 23rd Annual Needham Virtual Healthcare Conference
4 Apr 24
Arcellx to Participate at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
20 Mar 24
Arcellx to Participate at the TD Cowen 44th Annual Health Care Conference
29 Feb 24
Arcellx Provides Fourth Quarter and Year-End 2023 Financial Results and Business Highlights
28 Feb 24